Introduction
Semaglutide is a long-acting GLP-1 receptor agonist that has become one of the most widely studied peptides in contemporary metabolic and cardiovascular research. Its unique molecular design, combining high GLP-1 receptor affinity with extended plasma half-life, makes it a valuable research tool for investigating a broad range of physiological systems.
For research and laboratory use only. Not intended for human or veterinary administration.
Molecular Structure
Semaglutide shares approximately 94% amino acid sequence homology with native GLP-1(7-36) amide. Key structural modifications include:
- Aib substitution at position 8: Replacement of alanine with alpha-aminoisobutyric acid (Aib) confers resistance to DPP-4 cleavage, the primary mechanism of native GLP-1 degradation.
- Lysine substitution at position 34: Arginine at position 34 is replaced with lysine to provide an attachment point for the fatty acid chain.
- C18 fatty diacid chain: Attached via a linker to the lysine at position 26, enabling strong albumin binding. This albumin association is the primary mechanism responsible for Semaglutide’s extended half-life of approximately 7 days, compared to 2 minutes for native GLP-1.
Receptor Pharmacology
Semaglutide acts as a full agonist at the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor. Upon binding, GLP-1R activates adenylyl cyclase via Gαs, increasing intracellular cAMP. This triggers:
- Glucose-dependent insulin secretion from pancreatic beta cells
- Suppression of glucagon from alpha cells
- Delayed gastric emptying
- Hypothalamic appetite suppression via arcuate nucleus signalling
- Activation of vagal afferent pathways contributing to satiety
Metabolic Research Applications
Semaglutide has been extensively studied in preclinical models of:
- Obesity: Dose-dependent reductions in body weight through appetite suppression and reduced energy intake in rodent models.
- Type 2 diabetes: Improved glycaemic control, beta-cell preservation, and insulin sensitivity in diabetic animal models.
- Non-alcoholic steatohepatitis (NASH): Reduction in hepatic steatosis, inflammation, and fibrosis markers in diet-induced NASH models.
- Lipid metabolism: Reductions in LDL cholesterol, triglycerides, and hepatic lipid accumulation.
Cardiovascular Research
GLP-1 receptors are expressed in cardiac tissue, vascular endothelium, and smooth muscle. Semaglutide research has demonstrated:
- Reduced atherosclerotic plaque progression in ApoE knockout mouse models
- Anti-inflammatory effects on vascular endothelium
- Cardioprotective effects in ischaemia-reperfusion injury models
- Reduction in markers of cardiac inflammation and oxidative stress
Neurological Research
GLP-1 receptors are expressed throughout the central nervous system, including the hippocampus, cortex, and substantia nigra. Emerging research has investigated Semaglutide in models of:
- Neuroinflammation and microglial activation
- Parkinson’s disease — neuroprotection of dopaminergic neurons
- Alzheimer’s disease — reduction of amyloid burden and tau phosphorylation
- Cognitive function and hippocampal neurogenesis
Available Concentrations for Research
Vanta Labs supplies Semaglutide in the following concentrations to support dose-response and longitudinal research designs: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg.
Storage and Handling
Store lyophilised Semaglutide at −20°C, protected from light and moisture. Reconstitute with bacteriostatic water. Once reconstituted, store at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles. Do not agitate or vortex.
All products supplied by Vanta Labs are intended strictly for laboratory and research purposes.